<p>随着全球市场经历积极的企业盈利和上升的消费者通胀，科技行业继续吸引关注，纳斯达克综合指数等指数创下新高。在这个动态环境中，识别高增长科技股需要寻找那些不仅展现出强劲财务表现，而且在经济波动中表现出韧性和适应能力的公司。</p>
<h3>全球十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>金电路电子</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海华测导航技术</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜电子</td>
<td>26.23%</td>
<td>37.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>全球安全专家</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 745 只股票的完整列表。</p>
<p>让我们回顾一些我们筛选股票中的显著选择。</p>
<h2>上海电影 (SHSE:601595)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 上海电影有限公司在中国从事电影发行和放映活动，市值为 140.3 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过在中国的电影发行和放映活动产生收入。其市值为 140.3 亿人民币，专注于娱乐行业。</p>
<p>尽管上海电影去年盈利下降 20.4%，但预计将迎来强劲复苏，年盈利增长预计为 35.2%。这一增长率超过了中国市场 23.3% 的平均水平，突显了公司在娱乐行业的韧性和潜力。随着研发投资大幅集中于创新内容创作，显著的支出增强了其在快速变化的行业环境中的竞争优势，上海电影展现出良好的发展轨迹。该公司还受益于 4500 万人民币的可观一次性收益，提升了其财务状况，为未来扩张和更具活力的市场参与做好准备。</p>
<ul>
<li>在我们的健康报告中更详细地了解上海电影的潜力。</li>
<li>查看我们的历史业绩报告，以获取上海电影过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 7 月的 SHSE:601595 收入和支出明细</p>
<h2>HAND 企业解决方案 (SZSE:300170)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> HAND 企业解决方案有限公司在中国提供 ERP 实施咨询服务，市值为 190.2 亿人民币。</p>
<p><strong>运营：</strong> 该公司专注于在中国提供 ERP 实施咨询服务，致力于为客户提供量身定制的解决方案，以优化其业务流程，为其收入模式做出重要贡献。</p>
<p>HAND 企业解决方案展现出强劲的增长轨迹，预计年盈利将激增 26.3%，超过中国市场 23.3% 的平均水平。考虑到该公司最近转向盈利，这一表现尤为显著，反映了其运营效率和市场适应能力。该公司还坚定致力于股东回报，最近确认分红，每股现金分红为 0.48 元人民币。此外，HAND 在研发方面的战略重点显而易见，分配了大量资源用于创新，确保其在动态科技环境中保持竞争力。</p>
<ul>
<li>在我们的综合健康报告中深入了解 HAND 企业解决方案的复杂性。</li>
<li>通过我们的详细历史业绩报告评估 HAND 企业解决方案的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 7 月的 SZSE:300170 收入和支出明细</p>
<h2>华兰生物疫苗 (SZSE:301207)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 华兰生物疫苗有限公司专注于中国疫苗的研发、生产和销售，市值为 111.8 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过其疫苗产品产生收入，利用其在研发方面的专业知识。其对中国市场的关注得到了强大的生产和销售基础设施的支持。</p>
<p>华兰生物疫苗正处于一个转型阶段，预计年收入增长 36.1%，超过中国市场 12.4% 的扩张率。尽管去年面临显著的盈利下滑和 17.9% 的较低利润率（相比之前的 35%），公司的战略调整旨在增强治理和运营灵活性。这一积极的做法得到了积极的研发投资策略的支持，确保华兰在生物科技领域保持创新的前沿。预计年盈利将激增 49.8%，这些举措可能使华兰在竞争环境中处于有利地位。</p>
<ul>
<li>通过阅读我们的健康报告，深入了解华兰生物疫苗的表现。</li>
<li>检查华兰生物疫苗的过去表现报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth"/></p>
<p>深交所：301207 截至 2025 年 7 月的收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>点击此链接深入了解我们全球高增长科技和人工智能股票筛选器中的 745 家公司。</li>
<li>这些公司是否是您投资策略的一部分？使用 Simply Wall St 将您的持股整合到一个投资组合中，并通过我们全面的分析工具获得洞察。</li>
<li>Simply Wall St 是您解锁全球市场趋势的关键，是一款面向前瞻性投资者的免费用户友好应用程序。</li>
</ul>
<h2>寻找新视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

华兰生物

<p>随着全球市场看到企业盈利向好和消费者通胀上升，科技行业备受关注，纳斯达克综合指数创下新高。关键的高增长科技公司包括金环电子、上海华测导航技术和 Pharma Mar，展现出强劲的收入和盈利增长。像上海电影和 HAND 企业解决方案这样的显著选择表现出韧性和适应能力，预计盈利增长将超过市场平均水平。华兰生物疫苗也在寻求显著增长，专注于研发和运营改进。投资者被鼓励探索科技行业中的这些机会</p>

<p>As global markets experience a mix of positive corporate earnings and rising consumer inflation, the tech sector continues to draw attention with indices like the Nasdaq Composite reaching new highs. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that not only demonstrate robust financial performance but also show resilience to economic fluctuations and adaptability in the face of evolving market conditions.</p>
<div class="lb-trans"><p>随着全球市场经历积极的企业盈利和上升的消费者通胀，科技行业继续吸引关注，纳斯达克综合指数等指数创下新高。在这个动态环境中，识别高增长科技股需要寻找那些不仅展现出强劲财务表现，而且在经济波动中表现出韧性和适应能力的公司。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.23%</td>
<td>37.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>金电路电子</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海华测导航技术</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜电子</td>
<td>26.23%</td>
<td>37.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>全球安全专家</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 745 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 745 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些我们筛选股票中的显著选择。</p>
</div><h2>Shanghai Film (SHSE:601595)</h2>
<div class="lb-trans"><h2>上海电影 (SHSE:601595)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shanghai Film Co., Ltd. is involved in film distribution and screening activities in China, with a market cap of CN¥14.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海电影有限公司在中国从事电影发行和放映活动，市值为 140.3 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from film distribution and screening activities within China. It operates with a market cap of CN¥14.03 billion, focusing on the entertainment sector.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过在中国的电影发行和放映活动产生收入。其市值为 140.3 亿人民币，专注于娱乐行业。</p>
</div><p>Shanghai Film, despite recent challenges with a 20.4% drop in earnings last year, is poised for a robust recovery with projected annual earnings growth of 35.2%. This growth rate outpaces the Chinese market's average of 23.3%, underscoring the company's resilience and potential in the entertainment sector. With R&amp;D investments sharply focused on innovative content creation, evidenced by their significant spendings which bolstered their competitive edge in a rapidly evolving industry landscape, Shanghai Film demonstrates a promising trajectory. The firm also benefits from substantial one-off gains amounting to CN¥45M, enhancing its financial standing as it gears up for future expansions and more dynamic market engagement.</p>
<div class="lb-trans"><p>尽管上海电影去年盈利下降 20.4%，但预计将迎来强劲复苏，年盈利增长预计为 35.2%。这一增长率超过了中国市场 23.3% 的平均水平，突显了公司在娱乐行业的韧性和潜力。随着研发投资大幅集中于创新内容创作，显著的支出增强了其在快速变化的行业环境中的竞争优势，上海电影展现出良好的发展轨迹。该公司还受益于 4500 万人民币的可观一次性收益，提升了其财务状况，为未来扩张和更具活力的市场参与做好准备。</p>
</div><ul>
<li>Take a closer look at Shanghai Film's potential here in our health report.</li>
<li>Review our historical performance report to gain insights into Shanghai Film's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更详细地了解上海电影的潜力。</li>
<li>查看我们的历史业绩报告，以获取上海电影过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:601595 Revenue and Expenses Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 SHSE:601595 收入和支出明细</p>
</div><h2>HAND Enterprise Solutions (SZSE:300170)</h2>
<div class="lb-trans"><h2>HAND 企业解决方案 (SZSE:300170)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> HAND Enterprise Solutions Co., Ltd. offers ERP implementation consulting services in China and has a market cap of CN¥19.02 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> HAND 企业解决方案有限公司在中国提供 ERP 实施咨询服务，市值为 190.2 亿人民币。</p>
</div><p><strong>Operations:</strong> The company specializes in ERP implementation consulting services within China. It focuses on providing tailored solutions to optimize business processes for its clients, contributing significantly to its revenue model.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司专注于在中国提供 ERP 实施咨询服务，致力于为客户提供量身定制的解决方案，以优化其业务流程，为其收入模式做出重要贡献。</p>
</div><p>HAND Enterprise Solutions has demonstrated a robust growth trajectory, with earnings forecasted to surge by 26.3% annually, outpacing the broader Chinese market's average of 23.3%. This performance is particularly notable given the firm's recent transition to profitability, which reflects positively on its operational efficiency and market adaptability. The company also maintains a solid commitment to shareholder returns as evidenced by its recent dividend affirmation, distributing a cash dividend of CNY 0.48 per share. Moreover, HAND's strategic focus on R&amp;D is evident from its allocation of significant resources towards innovation—ensuring it remains competitive in the dynamic tech landscape.</p>
<div class="lb-trans"><p>HAND 企业解决方案展现出强劲的增长轨迹，预计年盈利将激增 26.3%，超过中国市场 23.3% 的平均水平。考虑到该公司最近转向盈利，这一表现尤为显著，反映了其运营效率和市场适应能力。该公司还坚定致力于股东回报，最近确认分红，每股现金分红为 0.48 元人民币。此外，HAND 在研发方面的战略重点显而易见，分配了大量资源用于创新，确保其在动态科技环境中保持竞争力。</p>
</div><ul>
<li>Navigate through the intricacies of HAND Enterprise Solutions with our comprehensive health report here.</li>
<li>Assess HAND Enterprise Solutions' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的综合健康报告中深入了解 HAND 企业解决方案的复杂性。</li>
<li>通过我们的详细历史业绩报告评估 HAND 企业解决方案的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300170 Revenue and Expenses Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 SZSE:300170 收入和支出明细</p>
</div><h2>Hualan Biological Vaccine (SZSE:301207)</h2>
<div class="lb-trans"><h2>华兰生物疫苗 (SZSE:301207)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Hualan Biological Vaccine Inc. focuses on the research, development, production, and sale of vaccines in China with a market cap of CN¥11.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 华兰生物疫苗有限公司专注于中国疫苗的研发、生产和销售，市值为 111.8 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its vaccine products, leveraging its expertise in research and development. Its focus on the Chinese market is supported by a robust production and sales infrastructure.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其疫苗产品产生收入，利用其在研发方面的专业知识。其对中国市场的关注得到了强大的生产和销售基础设施的支持。</p>
</div><p>Hualan Biological Vaccine is navigating a transformative phase, marked by a robust revenue forecast growth of 36.1% annually, outstripping the broader Chinese market's expansion rate of 12.4%. Despite recent challenges such as a significant earnings dip last year and lower profit margins at 17.9% compared to 35% previously, the company's strategic amendments aim to bolster governance and operational agility. This proactive approach is complemented by an aggressive R&amp;D investment strategy, ensuring Hualan remains at the forefront of innovation in the biotech sector. With earnings expected to surge by 49.8% per year, these initiatives could position Hualan favorably within its competitive landscape.</p>
<div class="lb-trans"><p>华兰生物疫苗正处于一个转型阶段，预计年收入增长 36.1%，超过中国市场 12.4% 的扩张率。尽管去年面临显著的盈利下滑和 17.9% 的较低利润率（相比之前的 35%），公司的战略调整旨在增强治理和运营灵活性。这一积极的做法得到了积极的研发投资策略的支持，确保华兰在生物科技领域保持创新的前沿。预计年盈利将激增 49.8%，这些举措可能使华兰在竞争环境中处于有利地位。</p>
</div><ul>
<li>Get an in-depth perspective on Hualan Biological Vaccine's performance by reading our health report here.</li>
<li>Examine Hualan Biological Vaccine's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的健康报告，深入了解华兰生物疫苗的表现。</li>
<li>检查华兰生物疫苗的过去表现报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:301207 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>深交所：301207 截至 2025 年 7 月的收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Click this link to deep-dive into the 745 companies within our Global High Growth Tech and AI Stocks screener.</li>
<li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li>
<li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接深入了解我们全球高增长科技和人工智能股票筛选器中的 745 家公司。</li>
<li>这些公司是否是您投资策略的一部分？使用 Simply Wall St 将您的持股整合到一个投资组合中，并通过我们全面的分析工具获得洞察。</li>
<li>Simply Wall St 是您解锁全球市场趋势的关键，是一款面向前瞻性投资者的免费用户友好应用程序。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

2025 年 7 月可供投资者探索的高增长科技股